Athyrium Opportunities Fund (AOF)

Athyrium Opportunities Fund1

Company Marketer / Counterparty Product Initial Investment Date
MedPro Safety Products Greiner Bio-One Vacuette Safety System February 2012
BioFire Diagnostics BioFire FilmArray September 2012
Verenium Verenium Various December 2012
Ironwood Pharmaceuticals Ironwood and Forest Laboratories Linzess January 2013
SynCardia Systems, Inc. SynCardia Total Artificial Heart March 2013
Progenity, Inc. Progenity, Inc. Various Genetic Tests June 2013
Tria Beauty, Inc. Tria Beauty Skincare Products July 2013
InnoPharma, Inc. Various Marketing Partners Specialty Injectable and Ophthalmic Generic Pharmaceuticals October 2013
Horizon Pharma, Inc. Horizon Pharma Various NSAIDs and ACTIMMUNE November 2013
Universal Biosensors, Inc. LifeScan (J&J) and Siemens Point of Care (POC) Diagnostics December 2013
Pernix Therapeutics Holdings, Inc. Pernix Treximet and Others February 2014
Ikaria, Inc. Ikaria INOMAX February 2014
VIVUS, Inc. VIVUS, Inc. Qsymia and STENDRA/SPEDRA February 2014
Synarc-Biocore Holdings, LLC Synarc-Biocore Holdings Specialty Clinical Research Services March 2014
Retrophin, Inc. Alamo Pharma Services, Inc. Chenodal / Thiola July 2014
Tecomet, Inc. Tecomet Orthopedic and Other Contract Manufacturing Services December 2014
Zealand Pharma A/S Sanofi Lyxumia December 2014
Lannett Company, Inc. Lannett Company, Inc. Generic Pharmaceuticals December 2015

1. This table lists all investments made by the Athyrium Opportunities Fund.